The 'New York Case'

Published: 07 April 2009

A great deal of publicity was given to the case of a man in New York who experienced rapid disease progression after infection with a strain of HIV resistant to three of the four classes of antiretroviral drugs. The man was diagnosed with HIV in December 2004, having previously received a negative test result in May 2003.

However, experts discussing the case at the Twelfth Conference on Retroviruses and Opportunistic Infections in Boston in early 2005 said that this isolated case report does not indicate that the HIV strain found in this patient is aggressive, since disease progression is determined by the complex interaction between the virus and the host's genetic make-up.1 2 In addition, the source patient for this man's HIV infection was identified and found not to have experienced rapid HIV disease progression despite extreme similarity between their viruses.3 This suggests that the host's immune response may be more important in determining the speed of progression than the virus's virulence.

Phenotypic analysis of the NYC man's virus revealed that it is fully susceptible to efavirenz and the fusion inhibitor T-20. While coverage of high-profile case studies such as this might suggest that infection with multidrug-resistant virus spells no treatment options, several studies suggest that this is not the case.

References

  1. Markowitz M et al. A case of apparent recent infection with a multi-drug-resistant and dual-tropic HIV-1 in association with rapid progression to AIDS. Twelfth Conference on Retroviruses and Opportunistic Infections, Boston, abstract 973B, 2005a
  2. Markowitz M et al. Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report. Lancet 365: 1031-1038, 2005b
  3. Blick G et al. "Patient zero": the Connecticut source of the multi-drug-resistant, dual-tropic, rapidly progressing HIV-1 strain found in NYC. Third International AIDS Society Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, abstract MoOa0101, 2005
This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.